Health care stocks were edging higher premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was up 0.9% and the iShares Biotechnology ETF (IBB) rose by 1.1% recently.
BeiGene (ONC) shares were slightly down after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of its drug Tevimbra in combination with gemcitabine and cisplatin as a first-line treatment for adults with recurrent or metastatic nasopharyngeal cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.